Argenx
ARGX
$995.15
Share price
6.36%
Change (1 day)
57.18%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Argenx (ARGX) - Net assets
Net assets on the balance sheet as of December 2024 : NZ$9.41 Billion
According to Argenx
's latest financial reports the company has NZ$9.41 Billion in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Argenx - Net assets on balance sheet (from 2021 to 2020)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2024-12-31 | $NZ$9.74 B | 50.47% |
| 2023-12-31 | $NZ$6.47 B | 46.2% |
| 2022-12-31 | $NZ$4.43 B | 19.45% |
| 2021-12-31 | $NZ$3.71 B | 30.01% |
| 2020-12-31 | $NZ$2.85 B | 45.34% |
| 2019-12-31 | $NZ$1.96 B | 86.93% |
| 2018-12-31 | $NZ$1.05 B | 50.24% |
| 2017-12-31 | $NZ$0.69 B | 590.77% |
| 2016-12-31 | $NZ$0.10 B | 55.44% |
| 2015-12-31 | $NZ$65.11 M | -31.12% |
| 2014-12-31 | $NZ$94.53 M | 87.68% |
| 2013-12-31 | $NZ$50.36 M | 88.12% |
| 2012-12-31 | $NZ$26.77 M | -42.32% |
| 2011-12-31 | $NZ$46.42 M | 163.13% |
| 2010-12-31 | $NZ$17.64 M |